1) Zomedia partners with CelSee to develop and market first canine cancer liquid biopsy. Zomedica plans on using Celsee's technology to develop and market a non-invasive diagnostic assay, called ZM-017, to help veterinarians diagnose cancer in dogs. According to Veterinary Cancer Society estimates, one in four dogs will develop cancer at some stage, and up to half of all dogs over the age of 10 years.
Zomedica expects to complete clinical validation of this CTC detection innovation in the first half of 2018 and begin marketing of during the second half of 2018.
From Zomedica and CelSee: "A liquid biopsy is a test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood, and may be used to help find cancer at an early stage. Circulating tumor cells, commonly referred to as CTCs, are cells that have shed from a primary tumor into neighboring blood vessels and are transported throughout the body’s circulatory system. The detection of CTCs in the blood could indicate a cancer diagnosis without the need for an invasive tissue biopsy.
Liquid biopsies may also be used to help plan treatment or to find out how well treatment is working or if cancer has come back. Being able to take multiple samples of blood over time may also help doctors understand what kind of molecular changes are taking place in a tumor. The commercially available Celsee CTC test is a fast and effective blood test with results available within four hours. Celsee’s proprietary platform enables capture and analysis of cancer cells, and obviates the need for painful, surgical biopsies by a simple blood test."
2) New paper published in the official journal of the American Association of Pharmaceutical Scientists (AAPS) titled: Intestinal Stem Cells to Advance Drug Development, Precision, and Regenerative Medicine: A Paradigm Shift in Translational Research. This research has direct implications for dogs and translational medical value for humans and animals.
3) A new survey reveals Primary Care Physicians (PCP's) may nor understand human obesity as well as the should. "Experience suggests that some physicians view obesity as a purely lifestyle condition rather than a chronic metabolic disease. Physicians may not be aware of the role of biological factors in causing weight regain after an initial weight loss." There are lessons for the veterinary profession in these publications.